Gilead Sciences, Inc. (GILD) vs Novartis AG (NVS)
Gilead Sciences, Inc. and Novartis AG are both Drug Manufacturers General companies. Novartis AG is the larger, with a market value of $264.3B against $183.2B — 1.4× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Novartis AG trades at 21.8×. Gilead Sciences, Inc. grew revenue faster over the last twelve months: 5.52% against 2.73%. Novartis AG has the higher net margin (22.5% vs −10.6%) and the higher return on invested capital (13.1% vs −4.48%). Both pay a dividend; Gilead Sciences, Inc. yields more (4.27% vs 3.69%). Across the 22 metrics below, Novartis AG leads on 12 and Gilead Sciences, Inc. on 10.
Valuation
Profitability
| Metric | GILD | NVS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.59% | 74.74% | 72.77% |
| Operating margin | (8.20%) | 30.17% | 18.90% |
| Net margin | (10.64%) | 22.50% | 8.27% |
| Free cash flow margin | 42.50% | 26.77% | 17.25% |
| Return on equity | (20.68%) | 30.37% | 6.97% |
| Return on assets | (6.17%) | 11.27% | 2.76% |
| Return on invested capital | (4.48%) | 13.14% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack